Abstract:Venous thromboembolism (VTE) involves the formation of a blood clot in a vein, and includes deep venous thrombosis (DVT) or pulmonary embolism (PE). The annual incidence for VTE varies from 0.75 to 2.69 per 1000 individuals, with about 40 million people worldwide impacted by VTE. Statins, 3‐hydroxy‐3‐methylglutaryl (HMG)‐coenzyme A (CoA) reductase inhibitors, inhibit cholesterol biosynthesis and display several vascular‐protective effects, including antithrombotic properties. However, the potential role of statins in the primary prevention of VTE is still not clear. To evaluate the benefits and risks of statins in preventing venous thromboembolism (VTE) in individuals with no prior history of VTE. We used standard Cochrane search methods. The search was last updated on 13 March 2023. We included randomized controlled trials (RCTs) comparing statins with any control intervention (including placebo and usual care) in healthy individuals or participants with conditions other than VTE. There were no restrictions on the dose, duration, route, or timing of statins. We used standard Cochrane methods. Our primary outcomes were VTE, DVT, and PE. Our secondary outcomes were serious adverse events, adverse events, and mortality. We used the trial sequential analysis (TSA) method to judge whether the evidence was sufficient, and we used the GRADE approach to assess the certainty of the evidence for each outcome. We included 27 RCTs involving 122,601 adults (aged 18 years and above) who were healthy, had various medical conditions (e.g. hypercholesterolemia), or were at risk for cardiovascular disease. Both males and females were included in all studies. Two studies focused solely on participants over 60 years of age. We deemed four studies to have a low risk of bias overall, while 19 were at high risk of bias, and four were unclear. The 27 studies compared use of statins versus placebo or usual care in individuals who had never experienced VTE. The statins used in the studies were atorvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin, and simvastatin. Twenty‐three studies followed up participants for over a year, with six of those extending follow‐ups for over five years. Twenty‐five studies were based in hospitals, and 24 studies were funded by industry. Only one study used VTE as a primary endpoint. The median incidence of VTE in the statins group was 0.72% (ranging from 0% to 10.53%), and in the control group it was 0.89% (ranging from 0% to 6.83%). Our pooled analysis of the 27 studies showed that, relative to control groups, statins may slightly reduce the overall incidence of VTE (odds ratio (OR) 0.86, 95% confidence intervals (CI) 0.76 to 0.98; 27 studies, 122,601 participants; low‐certainty evidence). Of the statins we evaluated, only rosuvastatin seemed to be associated with a reduced incidence of VTE, albeit the reduction in incidence was very small. The evidence did not clearly indicate a difference between groups in the incidence of DVT (OR 0.70, 95% CI 0.41 to 1.18; six studies, 40,305 participants; low‐certainty evidence), PE (OR 0.83, 95% CI 0.46 to 1.52; five studies, 28,427 participants; low‐certainty evidence), or myopathy (OR 1.10, 95% CI 0.83 to 1.45; 10 studies, 75,551 participants; low‐certainty evidence). Nonetheless, statin use might slightly decrease the incidence of any serious adverse event (OR 0.95, 95% CI 0.91 to 0.99; 13 studies, 67,020 participants; low‐certainty evidence) and any death (OR 0.90, 95% CI 0.86 to 0.95; 24 studies, 116,761 participants; low‐certainty evidence), compared to control. Using statins for the primary prevention of VTE may slightly reduce the incidence of VTE and all‐cause mortality. However, this effect is likely too weak to be considered significant. Statin use may not decrease the occurrence of DVT and PE. The current evidence is insufficient to draw strong conclusions because of the risk of bias in the studies, imprecision in the effect estimates, and potential publication bias. More evidence from well conducted and fully reported RCTs is needed to assess the preventive effects of different types of statins, as well as the effects of different dosages and treatment durations in various populations. Key messages ‐ Statin use for the primary prevention of venous thromboembolism (VTE; a condition in which a blood clot, or embolism, forms in the vein) may slightly decrease the incidence of VTE and death from any cause, but the reduction may be too small to be important. ‐ Statins may make no difference to the likelihood of experiencing deep vein thrombosis (DVT; a blood clot in the lower legs), pulmonary embolism (PE; a blood clot in the lungs), or myopathy (a condition affecting the skeletal muscles). ‐ Available evidence was limited, and we are not certain about its reliability. Future prospective studies should be well‐planned and conducted. They should involve a large number of peop -Abstract Truncated-

Statin use and mortality in patients with deep vein thrombosis. Data from the RIETE Registry

Statin Withdrawal Beyond Acute Phase Affected Outcome of Thrombolytic Stroke Patients

Prior Statin Use and Intravenous Thrombolysis in Acute Ischemic Stroke: a Meta-Analysis of Cohort Studies

Statins during Anticoagulation for Emergency Life-Threatening Venous Thromboembolism: A Review

Risk of Venous Thromboembolism in Statin Users Compared to Fibrate Users in the United Kingdom Clinical Practice Research Datalink (UK CPRD) GOLD

Early statin use is associated with improved survival and cardiovascular outcomes in patients with atrial fibrillation and recent ischaemic stroke: A propensity-matched analysis of a global federated health database

Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease

Statins use and recurrent venous thromboembolism in the direct oral anticoagulant era: insight from the COMMAND VTE Registry-2

Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related Mortality

Statin use in cirrhosis and its association with incidence of portal vein thrombosis

Statins for the primary prevention of venous thromboembolism

Assessment of bleeding events in patients receiving DOACs with or without statins to treat venous thromboembolism: insights from the RIETE registry

Effects of Statin Dose, Class, and Use Intensity on All-Cause Mortality in Patients with Type 2 Diabetes Mellitus

Prognostic Impact of Statins in Heart Failure with Preserved Ejection Fraction

The long-term usage of statin prevents adverse events in patients with atrial fibrillation

Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study

The association of statin use with in‐hospital mortality in patients with acute kidney injury during hospitalization: A retrospective analysis

Statin use and in-hospital outcomes among chronic kidney disease patients: a retrospective cohort study

Statin Use and High-Dose Statin Use after Ischemic Stroke in the UK: a Retrospective Cohort Study.

Early statin use is associated with improved outcomes in patients with atrial fibrillation and recent ischaemic stroke.

Statins and Mortality of Patients After Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-analysis